MENU
+Compare
SPRO
Stock ticker: NASDAQ
AS OF
Dec 26, 12:08 PM (EDT)
Price
$2.29
Change
-$0.05 (-2.14%)
Capitalization
131.83M

SPRO Spero Therapeutics Forecast, Technical & Fundamental Analysis

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm... Show more

SPRO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for SPRO with price predictions
Dec 24, 2025

SPRO in downward trend: price dove below 50-day moving average on December 23, 2025

SPRO moved below its 50-day moving average on December 23, 2025 date and that indicates a change from an upward trend to a downward trend. In of 31 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day moving average for SPRO crossed bearishly below the 50-day moving average on December 08, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SPRO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

SPRO broke above its upper Bollinger Band on December 22, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for SPRO entered a downward trend on December 12, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 72 cases where SPRO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on December 15, 2025. You may want to consider a long position or call options on SPRO as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for SPRO just turned positive on December 22, 2025. Looking at past instances where SPRO's MACD turned positive, the stock continued to rise in of 39 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SPRO advanced for three days, in of 205 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SPRO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.975) is normal, around the industry mean (26.541). P/E Ratio (10.751) is within average values for comparable stocks, (51.479). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.873). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (4.433) is also within normal values, averaging (311.015).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SPRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
SPRO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

SPRO is expected to report earnings to rise 53.85% to -20 cents per share on March 26

Spero Therapeutics SPRO Stock Earnings Reports
Q4'25
Est.
$-0.20
Q3'25
Beat
by $0.26
Q2'25
Beat
by $0.54
Q1'25
Beat
by $0.02
Q4'24
Missed
by $0.02
The last earnings report on November 13 showed earnings per share of -12 cents, beating the estimate of -38 cents. With 89.84K shares outstanding, the current market capitalization sits at 131.83M.
A.I. Advisor
published General Information

General Information

a developer of novel therapies for the treatment of resistant bacterial infections

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
675 Massachusetts Avenue
Phone
+1 857 242-1600
Employees
46
Web
https://www.sperotherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BRVO0.07N/A
N/A
Bravo Multinational Incorporated
HBSI43.35N/A
N/A
Highlands Bankshares, Inc.
IIDDY7.11N/A
N/A
IGO Ltd
VTAGY21.42N/A
N/A
VANTAGE TOWERS AG
CBLNF29.46N/A
N/A
Mersen

SPRO and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, SPRO has been loosely correlated with ASBP. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if SPRO jumps, then ASBP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPRO
1D Price
Change %
SPRO100%
+0.43%
ASBP - SPRO
58%
Loosely correlated
+2.21%
CLGN - SPRO
38%
Loosely correlated
N/A
XENE - SPRO
32%
Poorly correlated
+1.06%
MGTX - SPRO
30%
Poorly correlated
+5.08%
MTVA - SPRO
30%
Poorly correlated
+1.77%
More